NET vs. NEC Neuroendocrine Tumors: What's the Difference?

When you or a loved one is diagnosed with a neuroendocrine neoplasm (tumor) — which often starts in the GI tract, pancreas, or lungs — you might see the acronyms NET or NEC on your pathology report. While they sound very similar, they represent two distinct types of tumors with very different behaviors and treatment plans. Simply put, NET stands for Neuroendocrine Tumor, which is typically slower-growing and made of cells that look similar to normal cells. NEC stands for Neuroendocrine Carcinoma, which is fast-growing and made of cells that look very abnormal ^[1][2].

Understanding the difference between a NET and a NEC is crucial because this distinction heavily dictates the severity of the diagnosis and the types of treatments your care team will recommend ^[1][3].

Quick Comparison: NET vs. NEC

What is a Neuroendocrine Tumor (NET)?

A NET is described by pathologists as “well-differentiated.” This means that under a microscope, the tumor cells still look and act somewhat like normal, healthy neuroendocrine cells ^[1].

Key characteristics of NETs include:

• Slower Growth: NETs generally grow and spread at a slower rate, which usually translates to a more favorable long-term prognosis ^[4][5].
• Lower Proliferation Rate: Doctors measure how fast cells are dividing using a marker called the Ki-67 index, which is reported as a percentage. Most NETs have lower Ki-67 scores (typically under 20%), with the exception of Grade 3 NETs, which are discussed below ^[6][7].
• Targeted Treatments: Because they grow slower and maintain specific features on their cell surfaces, NETs are often treated with therapies that specifically target these traits. Common treatments include somatostatin analogs, peptide receptor radionuclide therapy (PRRT), or targeted oral medications ^[8][9].

What is a Neuroendocrine Carcinoma (NEC)?

A NEC is described as “poorly differentiated.” This means the tumor cells have mutated significantly and no longer resemble normal, healthy cells ^[1][2].

Key characteristics of NECs include:

• Aggressive Growth: NECs are fast-growing and tend to spread (metastasize) quickly. Because of this, a NEC diagnosis requires a prompt, proactive treatment plan from a specialized care team ^[4][5].
• High Proliferation Rate: NECs always have a very high Ki-67 index (greater than 20%, and frequently over 55%). This means a large percentage of the cells are actively dividing at any given time ^[7][4].
• Genetic Changes: NECs frequently have specific genetic mutations, such as the inactivation of the TP53 and RB1 genes, which drive their rapid growth ^[10][11].
• Chemotherapy-Based Treatments: Because NEC cells divide so rapidly and behave aggressively, they often respond better to traditional, platinum-based chemotherapy, and sometimes emerging treatments like immunotherapy ^[12][13].

The Exception: Grade 3 NETs

There is a specific, often-confusing subcategory called a Grade 3 NET. While Grade 3 NETs have a high Ki-67 index (over 20%, meaning fast growth) just like a NEC, their cells still look “well-differentiated” (like normal cells).

It is vital to know that a Grade 3 NET is a completely distinct diagnosis from a NEC, and it is usually treated differently. If your report shows a high Ki-67 index, your care team must determine if it is a Grade 3 NET or a true NEC by looking at cell differentiation and genetics ^[6][11].

Reading Your Pathology Report

To figure out whether a tumor is a NET or a NEC, a pathologist looks at a biopsy sample under a microscope. They focus on three main factors to classify your tumor:

1. Differentiation: How much the tumor cells look like normal cells (well-differentiated vs. poorly differentiated) ^[14].
2. Ki-67 Index: A chemical stain used to calculate the exact percentage of tumor cells that are actively dividing and preparing to multiply ^[14][6].
3. Mitotic Rate: While the Ki-67 test uses a chemical stain, the mitotic rate is a manual count. The pathologist literally counts the number of dividing cells (mitoses) they can see in a specific area under the microscope ^[14][6].